European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The American Thyroid Association (ATA) management guidelines for patients with thyroid nodules and differentiated thyroid cancer (DTC) are highly influential practice recommendations. The latest revision appeared in 2015 ("ATA 2015"). These guidelines were developed predominantly by North American experts. European experts frequently have different perspectives, given epidemiological, technological/methodological, practice organization, and medicolegal differences between the respective regions. SUMMARY: Divergent viewpoints were the focus of an invited symposium organized by the European Association of Nuclear Medicine involving 17 European thyroidologists, four ATA Guidelines Taskforce members, and an audience of 200 international experts. The group discussed the preoperative assessment of thyroid nodules, surgery and the role of pathology, radioiodine (RAI) therapy (RAIT), the assessment of initial therapy and dynamic risk stratification, and the treatment of persistent disease, recurrences, and advanced thyroid cancer. The dialogue resulted in this position paper contrasting European and ATA 2015 perspectives on key issues. One difference pertains to the permissiveness of ATA 2015 regarding lobectomy for primary tumors ≤4 cm. European panelists cited preclusion of RAIT, potential need for completion thyroidectomy, frequent inability to avoid chronic thyroid hormone replacement, and limitations of supportive evidence as arguments against widely applying lobectomy. Significant divergence involved ATA 2015's guidance regarding RAIT. European panelists favored wider use of postoperative RAIT than does ATA 2015. Rationales included the modality's association with favorable patient outcomes and generally limited toxicity, and lack of high-quality evidence supporting withholding RAIT. Additionally, European panelists favored recombinant human thyrotropin (rhTSH) in more settings than does ATA 2015, citing avoidance of hypothyroid morbidity and quality-of-life impairment, without apparent sacrifice in oncologic outcomes. Based on clinical evidence plus theoretical advantages, European experts advocated dosimetric versus fixed-activity RAIT approaches for advanced DTC. European panelists noted that the ATA 2015 risk-stratification system requires information sometimes unavailable in everyday practice. ATA 2015 recommendations regarding RAI-refractory DTC should consider potential palliative benefits of RAIT in patients who also have RAI-susceptible lesions. CONCLUSIONS: European panelists suggested modifications to approximately one-third of ATA 2015 recommendations. Varying European and ATA 2015 perspectives can stimulate analysis and discussion of the literature and performance of primary research to resolve discrepant recommendations and potentially improve patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Self-citationACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee
Tessler, F. N., Middleton, W. D., Grant, E. G., Hoang, J. K., Berland, L. L., Teefey, S. A., Cronan, J. J., Beland, M. D., Desser, T. S., Frates, M. C., et al. (2017) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2017.01.046 · Cited by 2,530 · cited 1×
“(28), including emerging and promising web-based versions.”
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096 · cited 1×
“Although kinase inhibitors were approved in some countries based on Phase II trials (133), the benefits of these drugs have been established in RCTs (134,135).”
Self-citationPacini, F., Schlumberger, M., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,976 · cited 1×
“…European panelists felt that a stronger endorsement of rhTSH preparation is warranted in most settings, as is found in the EANM guidelines for RAIT (87), European Society for Molecular Oncology thyroid cancer guidelines (88), or a European expert consensus statement (89) (Supplementary Table S3).”
Self-citationThe 2017 Bethesda System for Reporting Thyroid Cytopathology
Cibas, E. S., & Ali, S. Z. (2017) · Thyroid · doi:10.1089/thy.2017.0500 · Cited by 1,844 · cited 1×
“The recent update (29) of The Bethesda System for Reporting Thyroid Cytopathology is, in our opinion, an improvement over the previous version (30).”
Durante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J. D., De Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,675
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Self-citationNikiforov, Y. E., Seethala, R. R., Tallini, G., Baloch, Z. W., Basolo, F., Thompson, L. D. R., Barletta, J. A., Wenig, B. M., Al Ghuzlan, A., Kakudo, K., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0386 · Cited by 1,404 · cited 1×
“…with papillary-like nuclear fea-tures’’ classification and the finding of RAS mutations or PAX8-PPR c rearrangements, among others, in histolog-icallybenignnodules (39,40),together withthe increased emphasis on ultrasonography, may limit the role of molecular testing to ruling out malignancy (41).”
Self-citationRuss, G., Bonnema, S. J., Erdogan, M. F., Durante, C., Ngu, R., & Leenhardt, L. (2017) · European Thyroid Journal · doi:10.1159/000478927 · Cited by 1,284 · cited 3×
“Together with the simplicity of the system, these user-friendly features should promote inter-observer reproducibility of descriptions and facilitate the presentation of results (20).”
Self-citationFrancis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Self-citationThe Importance of Surgeon Experience for Clinical and Economic Outcomes From Thyroidectomy
Sosa, J. A., Bowman, H. M., Tielsch, J. M., Powe, N. R., Gordon, T. A., & Udelsman, R. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00005 · Cited by 1,118 · cited 1×
“EuropeanpanelistswelcomedATA2015’sinclusion(on pages32–33)oftextnotingtheassociationbetweengreater experienceinthyroidsurgeryandlowercomplicationrates (65–69).”
Self-citationKwak, J. Y., Han, K. H., Yoon, J. H., Moon, H. J., Son, E. J., Park, S. H., Jung, H. K., Choi, J. S., Kim, B. M., & Kim, E.-K. (2011) · Radiology · doi:10.1148/radiol.11110206 · Cited by 1,101 · cited 1×
“However, ATA 2015 might have recommended for this purpose the Thyroid Imaging Reporting and Database System (TIRADS), due toits extensive validation(19,20),albeitrecent literature (21–26) suggests comparable diagnostic performance for the system introduced in ATA 2015 versus assessed TIRADS…”
Sherma, S. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12488-9 · Cited by 925
Frequency of TERT promoter mutations in human cancers
Vinagre, J., Almeida, A., Pópulo, H., Batista, R., Lyra, J., Pinto, V., Coelho, R., Celestino, R., Prazeres, H., Lima, L., et al. (2013) · Nature Communications · doi:10.1038/ncomms3185 · Cited by 898 · cited 1×
“Several changes were suggested for recommendation 71, which addresses the optimal directed approach to patients with suspected structural neck recurrence.”
Self-citationSelumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
Self-citationNikiforov, Y. E., Ohori, N. P., Hodak, S. P., Carty, S. E., LeBeau, S. O., Ferris, R. L., Yip, L., Seethala, R. R., Tublin, M. E., Stang, M. T., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1469 · Cited by 790
Guidelines for radioiodine therapy of differentiated thyroid cancer
Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., & Bombardieri, E. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0883-1 · Cited by 727 · cited 1×
“…European panelists felt that a stronger endorsement of rhTSH preparation is warranted in most settings, as is found in the EANM guidelines for RAIT (87), European Society for Molecular Oncology thyroid cancer guidelines (88), or a European expert consensus statement (89) (Supplementary Table S3).”
Self-citationMolecular Testing for Mutations in Improving the Fine-Needle Aspiration Diagnosis of Thyroid Nodules
Nikiforov, Y. E., Steward, D. L., Robinson-Smith, T. M., Haugen, B. R., Klopper, J. P., Zhu, Z., Fagin, J. A., Falciglia, M., Weber, K., & Nikiforova, M. N. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0247 · Cited by 711 · cited 1×
“For ‘‘indeterminate’’ cytology samples (Bethesda clas-sifications of ‘‘atypia of undetermined significance/ follicular lesion of undetermined significance’’ or FN/ SFN), the principal purpose of molecular markers has been diagnostic (ruling malignancy in/out) (35–38).”
Extent of Surgery Affects Survival for Papillary Thyroid Cancer
Bilimoria, K. Y., Bentrem, D. J., Ko, C. Y., Stewart, A. K., Winchester, D. P., Talamonti, M. S., & Sturgeon, C. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e31814697d9 · Cited by 697 · cited 1×
“(58), have similar limitations to those of Adam et al .”
Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
Schlumberger, M., Catargi, B., Borget, I., Deandreis, D., Zerdoud, S., Bridji, B., Bardet, S., Leenhardt, L., Bastie, D., Schvartz, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108586 · Cited by 684 · cited 1×
“In our opinion, it is questionable whether postoperative 131 I should be administered for remnant ablation alone, especially given recent data from RCTs (76,77) and given improved ultrasound systems and Tg assays.”
Self-citationAblation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer
Mallick, U., Harmer, C., Yap, B., Wadsley, J., Clarke, S., Moss, L., Nicol, A., Clark, P. M., Farnell, K., McCready, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109589 · Cited by 615 · cited 7×
“However, two prospective, multicenter, RCTs—IoN from the United Kingdom (82) and ESTIMABL 2 from France (clinicaltrials.gov iden-tifiers NCT01398085 and NCT01837745, respectively)—are comparing 131 I, 1.11 GBq (30 mCi), versus no 131 I in low-risk and, in the case of IoN, also intermediate-risk patients.”
InfluentialSelf-citationRobbins, R. J., Wan, Q., Grewal, R. K., Reibke, R., Gonen, M., Strauss, H. W., Tuttle, R. M., Drucker, W., & Larson, S. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1534 · Cited by 587 · cited 1×
“For one, the text might suggest Tg rate of change in well differentiated tumors, for example doubling time (121–124), or fluorodeoxyglucose avidity (125,126) as potentially useful prognostic indicators.”
Self-citationTERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
Melo, M., da Rocha, A. G., Vinagre, J., Batista, R., Peixoto, J., Tavares, C., Celestino, R., Almeida, A., Salgado, C., Eloy, C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3734 · Cited by 555 · cited 1×
“Also, there was agreement with ATA 2015 repeatedly noting the emerging utility of TERT (70–73) and TP53 (74) mutations as potential unfavorable prognostic markers.”
Self-citationElisei, R., Bottici, V., Luchetti, F., Di Coscio, G., Romei, C., Grasso, L., Miccoli, P., Iacconi, P., Basolo, F., Pinchera, A., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030550 · Cited by 537
Self-citationTargeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer
Nikiforova, M. N., Wald, A. I., Roy, S., Durso, M. B., & Nikiforov, Y. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2292 · Cited by 485 · cited 1×
“Also, there was agreement with ATA 2015 repeatedly noting the emerging utility of TERT (70–73) and TP53 (74) mutations as potential unfavorable prognostic markers.”
Ladenson, P. W., Braverman, L. E., Mazzaferri, E. L., Brucker-Davis, F., Cooper, D. S., Garber, J. R., Wondisford, F. E., Davies, T. F., DeGroot, L. J., Daniels, G. H., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371304 · Cited by 466 · cited 1×
“These findings have been widely documented in RCTs and other clinical studies (90– 94) as well as patient surveys (84,95,96).”
Pacini, F., Ladenson, P. W., Schlumberger, M., Driedger, A., Luster, M., Kloos, R. T., Sherman, S., Haugen, B., Corone, C., Molinaro, E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1651 · Cited by 450
Self-citationAdam, M. A., Pura, J., Gu, L., Dinan, M. A., Tyler, D. S., Reed, S. D., Scheri, R., Roman, S. A., & Sosa, J. A. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000925 · Cited by 427 · cited 1×
“(57)— major evidence cited by ATA 2015 to support less extensive thyroid surgery—can be questioned on several counts.”
Self-citationLeenhardt, L., Erdogan, M. F., Hegedus, L., Mandel, S. J., Paschke, R., Rago, T., & Russ, G. (2013) · European Thyroid Journal · doi:10.1159/000354537 · Cited by 404
Self-citationHauch, A., Al-Qurayshi, Z., Randolph, G., & Kandil, E. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3846-8 · Cited by 377 · cited 1×
“EuropeanpanelistswelcomedATA2015’sinclusion(on pages32–33)oftextnotingtheassociationbetweengreater experienceinthyroidsurgeryandlowercomplicationrates (65–69).”
Leboulleux, S., Bastholt, L., Krause, T., de la Fouchardiere, C., Tennvall, J., Awada, A., Gómez, J. M., Bonichon, F., Leenhardt, L., Soufflet, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70335-2 · Cited by 375
Self-citationPAX8-PPARγ Rearrangement in Thyroid Tumors: RT-PCR and Immunohistochemical Analyses
Nikiforova, M. N., Biddinger, P. W., Caudill, C. M., Kroll, T. G., & Nikiforov, Y. E. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200208000-00006 · Cited by 349 · cited 1×
“For ‘‘indeterminate’’ cytology samples (Bethesda clas-sifications of ‘‘atypia of undetermined significance/ follicular lesion of undetermined significance’’ or FN/ SFN), the principal purpose of molecular markers has been diagnostic (ruling malignancy in/out) (35–38).”
Wang, W. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.3.1107 · Cited by 339
Russ, G., Royer, B., Bigorgne, C., Rouxel, A., Bienvenu-Perrard, M., & Leenhardt, L. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0936 · Cited by 327 · cited 2×
“Employing a TIRADS-based algorithm may reduce unneeded FNAs by an estimated 34% or more (27).”
InfluentialSelf-citationHaugen, B. R. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.11.3877 · Cited by 325
Iyer, N. G., Morris, L. G. T., Tuttle, R. M., Shaha, A. R., & Ganly, I. (2011) · Cancer · doi:10.1002/cncr.26070 · Cited by 321 · cited 2×
“For RAIT of known disease, 3.7–7.4 GBq (100–200 mCi) activities are mentioned in recommendations 77B, 78, and 79B to treat patients < 70 years old who have iodine-avid pulmonary micrometastases, pulmonary macronodular metastases, or bone metastases, respectively; 5.55 GBq (150 mCi) is advocated as…”
InfluentialSelf-citationHiggins, T. S., Gupta, R., Ketcham, A. S., Sataloff, R. T., Wadsworth, J. T., & Sinacori, J. T. (2011) · The Laryngoscope · doi:10.1002/lary.21578 · Cited by 296
Prognosis and Treatment of Brain Metastases in Thyroid Carcinoma
Chiu, A. C. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.11.3637 · Cited by 295
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Pacini, F., Castagna, M. G., Brilli, L., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds230 · Cited by 290
for the German Societies of General and Visceral Surgery; Endocrinology; Nuclear Medicine; Pathology; Radiooncology; Oncological Hematology; and the German Thyroid Cancer Patient Support Organization Ohne Schilddrüse leben e.V., Dralle, H., Musholt, T. J., Schabram, J., Steinmüller, T., Frilling, A., Simon, D., Goretzki, P. E., Niederle, B., Scheuba, C., et al. (2013) · Langenbeck's Archives of Surgery · doi:10.1007/s00423-013-1057-6 · Cited by 279
Self-citationCastagna, M. G., Maino, F., Cipri, C., Belardini, V., Theodoropoulou, A., Cevenini, G., & Pacini, F. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0466 · Cited by 275
Sawka, A. M., Brierley, J. D., Tsang, R. W., Thabane, L., Rotstein, L., Gafni, A., Straus, S., & Goldstein, D. P. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.02.007 · Cited by 273 · cited 1×
“Omitting RAIT would eliminate that intervention’s possible outcome benefits, and would eliminate RAIT’s potential diagnostic contributions, for example, highly sensitive post-therapy scintigraphy and more sensitive follow-up thyroglobulin (Tg) determination and ‘‘diagnostic’’ scintigraphy (53–55).”
Pacini, F. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4092 · Cited by 268
Ruel, E., Thomas, S., Dinan, M., Perkins, J. M., Roman, S. A., & Sosa, J. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4332 · Cited by 268 · cited 2×
“Lastly, modification regarding the text on ‘‘blind’’ RAIT in patients with substantially elevated or rapidly rising Tg, or increasing anti-Tg antibody levels but negative ‘‘diagnostic’’ imaging (recommendations 80 and 81) in ATA 2015 was suggested.”
Self-citationRandolph, G. W., & Kamani, D. (2006) · Surgery · doi:10.1016/j.surg.2005.08.009 · Cited by 267
Miyauchi, A., Kudo, T., Miya, A., Kobayashi, K., Ito, Y., Takamura, Y., Higashiyama, T., Fukushima, M., Kihara, M., Inoue, H., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0355 · Cited by 265
Duclos, A., Peix, J.-L., Colin, C., Kraimps, J.-L., Menegaux, F., Pattou, F., Sebag, F., Touzet, S., Bourdy, S., Voirin, N., et al. (2012) · BMJ · doi:10.1136/bmj.d8041 · Cited by 261
Lassmann, M., Hänscheid, H., Chiesa, C., Hindorf, C., Flux, G., & Luster, M. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0761-x · Cited by 251
Self-citationAmerican Thyroid Association Statement on Preoperative Imaging for Thyroid Cancer Surgery
Yeh, M. W., Bauer, A. J., Bernet, V. A., Ferris, R. L., Loevner, L. A., Mandel, S. J., Orloff, L. A., Randolph, G. W., Steward, D. L., & for the American Thyroid Association Surgical Affairs Committee Writing Task Force (2015) · Thyroid · doi:10.1089/thy.2014.0096 · Cited by 246 · cited 2×
“European panelists generally agreed with recommendations 13–18 regarding molecular testing of FNA samples.”
Yoon, J. H., Lee, H. S., Kim, E.-K., Moon, H. J., & Kwak, J. Y. (2016) · Radiology · doi:10.1148/radiol.2015150056 · Cited by 232 · cited 1×
“…ATA 2015 might have recommended for this purpose the Thyroid Imaging Reporting and Database System (TIRADS), due toits extensive validation(19,20),albeitrecent literature (21–26) suggests comparable diagnostic performance for the system introduced in ATA 2015 versus assessed TIRADS variants.”
Momesso, D. P., Vaisman, F., Yang, S. P., Bulzico, D. A., Corbo, R., Vaisman, M., & Tuttle, R. M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4290 · Cited by 231 · cited 1×
“European investigators noted that ATA risk stratification schemes derive largely from data from patients treated more intensively than is advocated in ATA 2015, albeit new literature is appearing regarding such schemes in less intensively treated patients (111).”
Self-citationVerloop, H., Louwerens, M., Schoones, J. W., Kievit, J., Smit, J. W. A., & Dekkers, O. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1063 · Cited by 220 · cited 1×
“Additionally, although avoiding postsurgical thyroid hormone therapy is sometimes given as a rationale for less extensive resection, in Europe, up to 75% of lobectomized patients may ultimately be candidates for such therapy (50– 52).”
Self-citationThe impact of surgical volume on patient outcomes following thyroid surgery
Kandil, E., Noureldine, S. I., Abbas, A., & Tufano, R. P. (2013) · Surgery · doi:10.1016/j.surg.2013.04.068 · Cited by 218
Middleton, W. D., Teefey, S. A., Reading, C. C., Langer, J. E., Beland, M. D., Szabunio, M. M., & Desser, T. S. (2018) · American Journal of Roentgenology · doi:10.2214/ajr.17.18822 · Cited by 206 · cited 1×
“…ATA 2015 might have recommended for this purpose the Thyroid Imaging Reporting and Database System (TIRADS), due toits extensive validation(19,20),albeitrecent literature (21–26) suggests comparable diagnostic performance for the system introduced in ATA 2015 versus assessed TIRADS variants.”
Lewis, B. D., Hay, I. D., Charboneau, J. W., McIver, B., Reading, C. C., & Goellner, J. R. (2002) · American Journal of Roentgenology · doi:10.2214/ajr.178.3.1780699 · Cited by 200
Routine Measurement of Plasma Calcitonin in Nodular Thyroid Diseases
Vierhapper, H. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.5.1589 · Cited by 192
Cheung, K., Roman, S. A., Wang, T. S., Walker, H. D., & Sosa, J. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2496 · Cited by 191
Self-citationUse of Radioactive Iodine for Thyroid Cancer
Haymart, M. R. (2011) · JAMA · doi:10.1001/jama.2011.1139 · Cited by 189 · cited 1×
“We would favor retaining the longstanding, widely applied practice (83,84) of postoperative RAIT in low-risk and intermediate-risk DTC patients until these studies reach conclusions suggesting that practice should be changed.”
Detection of the PAX8-PPARγ Fusion Oncogene in Both Follicular Thyroid Carcinomas and Adenomas
Cheung, L., Messina, M., Gill, A., Clarkson, A., Learoyd, D., Delbridge, L., Wentworth, J., Philips, J., Clifton-Bligh, R., & Robinson, B. G. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021020 · Cited by 188
Sobrinho-Simões, M., Eloy, C., Magalhães, J., Lobo, C., & Amaro, T. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.133 · Cited by 172 · cited 1×
“We refer to terminology such as ‘‘acceptable alternative’’ (recommendation 54A), ‘‘may be considered as an alternative’’ (recommendation 54B), ‘‘should be considered’’ (recommendation 54D), and ‘‘may be indicated in selected patients’’ (recommendation 75).”
Self-citationNational trends in thyroid surgery and the effect of volume on short‐term outcomes
Loyo, M., Tufano, R. P., & Gourin, C. G. (2013) · The Laryngoscope · doi:10.1002/lary.23923 · Cited by 171
Hahm, J. R., Lee, M.-S., Min, Y.-K., Lee, M.-K., Kim, K.-W., Nam, S. J., Yang, J.-H., & Chung, J. H. (2001) · Thyroid · doi:10.1089/10507250150500694 · Cited by 168 · cited 1×
“Calci-tonin screening permits earlier detection of medullary thyroid cancer (MTC), which may alter patient care, and European and other studies have suggested the strategy’s cost-effectiveness (10–14).”
TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease
Melo, M., da Rocha, A. G., Batısta, R., Vinagre, J., Martins, M. J., Costa, G., Ribeiro, C., Carrilho, F., Leite, V. A. P. H., Lobo, C., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2785 · Cited by 148
Self-citationDetermination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls
Costante, G., Durante, C., Francis, Z., Schlumberger, M. J., & Filetti, S. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet1023 · Cited by 143 · cited 1×
“ATA 2015 (in recommendation 4), as well as other European experts (15), take neutral positions on routinely measuring this analyte.”
Lee, J., Yun, M. J., Nam, K. H., Chung, W. Y., Soh, E.-Y., & Park, C. S. (2010) · Thyroid · doi:10.1089/thy.2009.0187 · Cited by 137 · cited 2×
“These findings have been widely documented in RCTs and other clinical studies (90– 94) as well as patient surveys (84,95,96).”
Heilo, A., Sigstad, E., Fagerlid, K. H., Håskjold, O. I., Grøholt, K. K., Berner, A., Bjøro, T., & Jørgensen, L. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2952 · Cited by 136
HAY, I. D., Lee, R. A., Davidge-Pitts, C. J., Reading, C. C., & Charboneau, J. W. (2013) · Surgery · doi:10.1016/j.surg.2013.07.007 · Cited by 130
Kłubo-Gwieździńska, J., Nostrand, D. V., Atkins, F., Burman, K. D., Jonklaas, J., Mete, M., & Wartofsky, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0494 · Cited by 128
Self-citationMarti, J. L., Jain, K., & Morris, L. G. T. (2015) · Thyroid · doi:10.1089/thy.2015.0067 · Cited by 122 · cited 1×
“These effects, although infrequent and mild relative to those of many oncologic therapies, can include an increased risk of a second primary malignancy (78,79).”
Verburg, F. A., de Keizer, B., Lips, C. J. M., ZELISSEN, P. M. J., & de Klerk, J. M. H. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01819 · Cited by 120
Self-citationSuh, C. H., Baek, J. H., Choi, Y. J., & Lee, J. H. (2016) · Thyroid · doi:10.1089/thy.2015.0545 · Cited by 118
Crippa, S., Cibas, E. S., Mazzucchelli, L., & Ali, S. Z. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpxm9wirq8jzbj · Cited by 117 · cited 1×
“The recent update (29) of The Bethesda System for Reporting Thyroid Cytopathology is, in our opinion, an improvement over the previous version (30).”
Performance of Elastography for the Evaluation of Thyroid Nodules: A Prospective Study
Azizi, G., Keller, J., Lewis, M., Puett, D., Rivenbark, K., & Malchoff, C. D. (2012) · Thyroid · doi:10.1089/thy.2012.0227 · Cited by 114
Lippi, F., Capezzone, M., Angelini, F., Taddei, D., Molinaro, E., Pinchera, A., & Pacini, F. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440005 · Cited by 113
Verburg, F. A., Stokkel, M. P. M., Dueren, C., Verkooijen, R. B. T., Mäder, U., van Isselt, J. W., Marlowe, R. J., Smit, J. W. A., Reiners, C., & Luster, M. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1315-6 · Cited by 111
Self-citationVerburg, F. A., Aktolun, C., Chiti, A., Frangos, S., Giovanella, L., Hoffmann, M., Iakovou, I. P., Mihailovic, J. M., Krause, B. J., Langsteger, W., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3327-3 · Cited by 111
Self-citationKluijfhout, W. P., Pasternak, J. D., Lim, J. K. J., Kwon, J. S., Vriens, M. R., Clark, O. H., Shen, W. T., Gosnell, J. E., Suh, I., & Duh, Q. (2016) · Thyroid · doi:10.1089/thy.2015.0495 · Cited by 111 · cited 2×
“…in ATA 2015 of the frequent lack of availability in ‘‘real-world’’ clinical practice of data necessary for complete initial postoperative classification of persistent/recurrent disease risk according to the modified ATA 2009 system, routine use of which is advocated in ATA 2015 recommendation 48.”
Taïeb, D., Sebag, F., Cherenko, M., Baumstarck‐Barrau, K., Fortanier, C., Farman‐Ara, B., De Micco, C., Vaillant, J., Thomas, S., Conte‐Devolx, B., et al. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03424.x · Cited by 105 · cited 1×
“Regarding recommendation 93, which offers guidance on directed therapy of advanced DTC, based on their clinical experience, the panelists suggested that part A, describing radiofrequency ablation, cryoablation, and stereotactic radiation as ‘‘valid alternatives’’ to surgery, could perhaps be strong.”
Grani, G., Lamartina, L., Ascoli, V., Bosco, D., Nardi, F., D’Ambrosio, F., Rubini, A., Giacomelli, L., Biffoni, M., Filetti, S., et al. (2016) · Endocrine · doi:10.1007/s12020-016-1148-6 · Cited by 104
Giovanella, L., Trimboli, P., Verburg, F. A., Treglia, G., Piccardo, A., Foppiani, L., & Ceriani, L. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2370-6 · Cited by 103
Self-citationDeandreis, D., Rubino, C., Tala, H., Leboulleux, S., Terroir, M., Baudin, É., Larson, S. M., Fagin, J. A., Schlumberger, M. J., & Tuttle, R. M. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.179606 · Cited by 103 · cited 1×
“(105) arguably may be viewed as additional evidence favoring dosimetric approaches as well as higher cumulative activities.”
Self-citationOperative management of locally advanced, differentiated thyroid cancer
Wang, L. Y., Nixon, I. J., Patel, S. G., Palmer, F. L., Tuttle, R. M., Shaha, A. R., Shah, J. P., & Ganly, I. (2016) · Surgery · doi:10.1016/j.surg.2016.04.027 · Cited by 96 · cited 2×
“According to ATA 2015 recommendations 41 and 44, such examination should be reserved for certain subgroups: preoperatively, patients with voice abnormalities, a history of cervical or upper chest surgery placing the recurrent laryngeal nerve or vagus nerve at risk, or known posterior extrathyroidal…”
Self-citationClayman, G. L., Agarwal, G., Edeiken, B. S., Waguespack, S. G., Roberts, D. B., & Sherman, S. I. (2011) · Thyroid · doi:10.1089/thy.2011.0170 · Cited by 95 · cited 1×
“…only moderate-quality evidence supporting single absolute values as cutoffs, on the inability of current imaging techniques to determine exact tumor dimensions on a millimeter scale accurately, and on the favorable long-term outcomes reported for such surgery, albeit in highly skilled hands (113).”
Verburg, F. A., Mäder, U., Reiners, C., & Hänscheid, H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1631 · Cited by 92 · cited 2×
“A large long-term analysis of the Wu¨rzburg DTC Database ( N = 1298; follow-up ‡ 5 years per patient) (85) showed sig-nificantly higher DTC-specific survival ( p = 0.002) in ETA low-risk patients ‡ 45 years old who received > 2.0 GBq ( > 54 mCi) versus £ 2.0 GBq as the first postoperative activity.”
InfluentialSelf-citationMallick, U. K., Harmer, C., Hackshaw, A. K., & Moss, L. (2012) · Clinical Oncology · doi:10.1016/j.clon.2012.01.001 · Cited by 89 · cited 2×
“However, two prospective, multicenter, RCTs—IoN from the United Kingdom (82) and ESTIMABL 2 from France (clinicaltrials.gov iden-tifiers NCT01398085 and NCT01837745, respectively)—are comparing 131 I, 1.11 GBq (30 mCi), versus no 131 I in low-risk and, in the case of IoN, also intermediate-risk patients.”
InfluentialThyroid Nodules with Bethesda System III Cytology: Can Ultrasonography Guide the Next Step?
Gweon, H. M., Son, E. J., Youk, J. H., & Kim, J. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2990-x · Cited by 85 · cited 1×
“However, with ‘‘inadequate’’ samples, the current best strategy would appear to be to repeat FNA, to re-evaluate sonographic features, or to do both (33,34).”
Yoo, W. S., Choi, H. S., Cho, S. W., Moon, J. H., Kim, K. W., Park, H. J., Park, S. Y., Choi, S. I., Choi, S. H., Lim, S. K., et al. (2013) · Clinical Endocrinology · doi:10.1111/cen.12348 · Cited by 85
Turska, M., Jarząb, B., Handkiewicz-Junak, D., Roskosz, J., Puch, Z., Wygoda, Z., Kukulska, A., Jurecka‐Lubieniecka, B., Hasse-Lazar, K., & Zajusz, A. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1190-5 · Cited by 85 · cited 1×
“Compared with THW, rhTSH sometimes (127–130), if not always (131), mitigates these phenomena in patients with distant DTC lesions, presumably because rhTSH is associated with much shorter-lived TSH elevations (132).”
Self-citationTotal Thyroidectomy for Benign Thyroid Disease
Barczyński, M., Konturek, A. J., Stopa, M., Cichoń, S., Richter, P., & Nowak, W. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3182360118 · Cited by 80 · cited 1×
“Also, patients undergoing lobectomy may run an appreciable risk of needing completion total thyroidectomy (46,47) due to the discovery of high-risk features only detectable postoperatively (48).”
Self-citationVerburg, F. A., Hänscheid, H., Biko, J., Hategan, M., Laßmann, M., Kreissl, M. C., Reiners, C., & Luster, M. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1303-x · Cited by 78 · cited 1×
“A fourth European difference with ATA 2015’s section on RAIT was the guidelines’ lack of a stance favoring dosimetry (99–103) versus ‘‘empiric’’ fixed activity use in 131 I treatment of advanced locoregional or distantly metastatic disease.”
Self-citationHugo, J., Robenshtok, E., Grewal, R. K., Larson, S. M., & Tuttle, R. M. (2012) · Thyroid · doi:10.1089/thy.2012.0183 · Cited by 75 · cited 2×
“Similar results were seen in a medium-term U.S. study of ATA 2009 intermediate-and high-risk patients (98).”
Self-citationTreglia, G., Caldarella, C., Saggiorato, E., Ceriani, L., Orlandi, F., Salvatori, M., & Giovanella, L. (2013) · Endocrine · doi:10.1007/s12020-013-9932-z · Cited by 75
Kluijfhout, W. P., Pasternak, J. D., Drake, F. T., Beninato, T. M., Shen, W. T., Gosnell, J. E., Suh, I., Liu, C., & Duh, Q. (2016) · Surgery · doi:10.1016/j.surg.2016.05.056 · Cited by 75 · cited 2×
“The guidelines note (on page 47, in explanatory text regarding recommendation 49) the challenge of obtaining adequate information for risk stratification from biochemical testing and imaging.”
Thyroid Cancer Alliance, Banach, R., Bartès, B., Farnell, K., Rimmele, H., Shey, J., Singer, S., Verburg, F. A., & Luster, M. (2013) · HORMONES · doi:10.1007/bf03401308 · Cited by 71 · cited 3×
“These findings have been widely documented in RCTs and other clinical studies (90– 94) as well as patient surveys (84,95,96).”
Self-citationGiovanella, L., Campennì, A., Treglia, G., Verburg, F. A., Trimboli, P., Ceriani, L., & Bongiovanni, M. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3285-1 · Cited by 68
Self-citationPiccardo, A., Puntoni, M., Treglia, G., Foppiani, L., Bertagna, F., Paparo, F., Massollo, M., Dib, B., Paone, G., Arlandini, A., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1199 · Cited by 68 · cited 1×
“Second, based on preliminary data, modalities for molecular imaging of nodules (143–149) beyond fluorodeoxyglucose-positron emission tomography may represent comparably accurate and less costly alternatives to DTC-associated mutation analysis, and would appear to warrant further exploration.”
Huang, T., Lai, J.-H., Wu, M., Chen, S.-L., Wu, C., & Tam, K. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-191 · Cited by 67 · cited 1×
“Also desirable would be to add to initial work (154) further formal assessment of the use and feasibility (155,156) of ATA 2015 and similar guidelines in Europe.”
Molinaro, E., Giani, C., Agate, L., Biagini, A., Pieruzzi, L., Bianchi, F., Brozzi, F., Ceccarelli, C., Viola, D., Piaggi, P., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4137 · Cited by 66
Self-citationChen, X., Wan, P., Yu, Y., Li, M., Xu, Y., Huang, P., & Huang, Z. (2014) · Journal of Voice · doi:10.1016/j.jvoice.2014.02.003 · Cited by 66 · cited 1×
“Ad-ditionally,suchdiagnosisprovidesvaluableinputfordecision makingregardingre-operation,orregardinganyneededreme-dialinterventions,whichmaybemoreefficaciousifundertaken sooner(62,63).”
Tuttle, R. M., Lopez, N., Leboeuf, R., Minkowitz, S. M., Grewal, R. K., Brokhin, M., Omry, G., & Larson, S. M. (2010) · Thyroid · doi:10.1089/thy.2009.0401 · Cited by 65 · cited 2×
“Lastly, modification regarding the text on ‘‘blind’’ RAIT in patients with substantially elevated or rapidly rising Tg, or increasing anti-Tg antibody levels but negative ‘‘diagnostic’’ imaging (recommendations 80 and 81) in ATA 2015 was suggested.”
Self-citationLamartina, L., Durante, C., Lucisano, G., Grani, G., Bellantone, R. D. A., Lombardi, C. P., Pontecorvi, A., Arvat, E., Felicetti, F., Zatelli, M. C., et al. (2017) · Thyroid · doi:10.1089/thy.2017.0299 · Cited by 65 · cited 1×
“Also desirable would be to add to initial work (154) further formal assessment of the use and feasibility (155,156) of ATA 2015 and similar guidelines in Europe.”
Variation in the Management of Thyroid Cancer
Haymart, M. R., Banerjee, M., Yang, D., Stewart, A. K., Sisson, J. C., Koenig, R. J., Doherty, G. M., & Griggs, J. J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3355 · Cited by 64 · cited 1×
“Thus, evidence often comprises conflicting observational studies, limiting its quality and rendering interpretation complex (150,151).”
Bardet, S., Ciappuccini, R., Pellot-Barakat, C. J. M., Monpeyssen, H., Michels, J.-J., Tissier, F., Blanchard, D., Ménégaux, F., Raucourt, D. D., Lefort, M., et al. (2017) · Thyroid · doi:10.1089/thy.2017.0293 · Cited by 59 · cited 1×
“First, ultrasound elastography might perhaps have been noted as an adjunctive method worthy of study in nodules with an FN/SFN Bethesda classification, as some but not all reports (137–142) suggest promising results.”
Self-citationChng, C. L., Tan, H., Too, C., Lim, W., Chiam, P., Zhu, L., Nadkarni, N. V., & Lim, A. (2018) · Singapore Medical Journal · doi:10.11622/smedj.2018062 · Cited by 57
Management of Invasive Differentiated Thyroid Cancer
Nixon, I. J., Simó, R., Newbold, K. L., Rinaldo, A., Suarez, C. M., Kowalski, L. P., Silver, C. E., Shah, J. P., & Ferlito, A. (2016) · Thyroid · doi:10.1089/thy.2016.0064 · Cited by 56
Self-citationChami, R., Moreno‐Reyes, R., & Corvilain, B. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1003 · Cited by 56
Moon, H. J., Kwak, J. Y., Kim, E., Choi, J. R., Hong, S. W., Kim, M. J., & Son, E. J. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0644-9 · Cited by 51
GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma
Spano, J., Vano, Y.-A., Vignot, S., Rouge, T. D. L. M., Hassani, L., Mouawad, R., Ménégaux, F., Khayat, D., & Leenhardt, L. (2011) · Medical Oncology · doi:10.1007/s12032-011-0070-2 · Cited by 39 · cited 1×
“…by using the phrase ‘‘newer cytotoxic chemotherapy agents or newer combinations of chemotherapy agents’’ (e.g., gemcitabine plus oxaliplatin) (136) and adding text stating that ‘‘conventional’’ cytotoxic chemotherapy is not recommended in DTC. European panelists also suggested adding content…”
Self-citationElisei, R., & Romei, C. (2013) · Thyroid Research · doi:10.1186/1756-6614-6-s1-s2 · Cited by 39
Self-citationSzintigraphisch mehranreichernde Schilddrüsenknoten gehen überwiegend mit normwertigem TSH einher
Kandror, T., Kuschnerus, S., Zimny, M., Pink, R., PALMEDO, H., Hach, A., Rau, H., Tanner, C., Zaplatnikov, K., Bockisch, A., et al. (2011) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0386-11-02 · Cited by 39
Barczyński, M., Konturek, A. J., Hubalewska–Dydejczyk, A., Gołkowski, F., & Nowak, W. (2017) · World Journal of Surgery · doi:10.1007/s00268-017-4230-1 · Cited by 39 · cited 1×
“Also, patients undergoing lobectomy may run an appreciable risk of needing completion total thyroidectomy (46,47) due to the discovery of high-risk features only detectable postoperatively (48).”
Self-citationRadioiodine Treatment of Thyroid Cancer with the Aid of Recombinant Human Thyrotropin
Adler, M. L., Macapinlac, H. A., & Robbins, R. J. (1998) · Endocrine Practice · doi:10.4158/ep.4.5.282 · Cited by 38
Essentials of Thyroid Cancer Management
Amdur, R. J., & Mazzaferri, E. L. (2005) · Springer eBooks · doi:10.1007/b135902 · Cited by 36
Giovanella, L., D’Aurizio, F., Campennì, A., Ruggeri, R. M., Baldari, S., Verburg, F. A., Trimboli, P., & Ceriani, L. (2016) · Endocrine · doi:10.1007/s12020-016-1094-3 · Cited by 33 · cited 1×
“In this situation, TSH values within the reference range may not always suffice to rule out thyroid autonomy in a substantial percentage of patients (4–8).”
Self-citationFrangos, S., Iakovou, I. P., Marlowe, R. J., Eftychiou, N., Patsali, L., Vanezi, A., Savva, A., Mpalaris, V., & Giannoula, E. I. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3124-4 · Cited by 20 · cited 2×
“Thus, unsurprisingly, European (110) as well as Latin American and Japanese clinicians (152) have noted that regional differences complicate the applicability of ATA thyroid nodule/DTC guidelines outside North America.”
Thyroid lobectomy is an effective option for unilateral benign nodular disease
Lytrivi, M., Kyrilli, A., Burniat, A., Patino, M. R., Sokolow, Y., & Corvilain, B. (2016) · Clinical Endocrinology · doi:10.1111/cen.13088 · Cited by 17 · cited 1×
“The first element was ATA 2015’s somewhat limited indications for high-activity postoperative RAIT of DTC (recommendation 51; Supplementary Table S2).”
Boaventura, P., Batısta, R., Pestana, A., Reis, M., Mendes, A., Eloy, C., Sobrinho-Simões, M. A., & Soares, P. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0740 · Cited by 13 · cited 2×
“ATA 2015 recommendation 73 acknowledges ‘‘theoretical advan-tages’’ of dosimetric approaches versus empiric activity use.”
Self-citationAlba, M., Fintini, D., Lovicu, R. M., Paragliola, R. M., Papi, G., Rota, C. A., Pontecorvi, A., & Corsello, S. M. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345722 · Cited by 9 · cited 1×
“Additionally, although avoiding postsurgical thyroid hormone therapy is sometimes given as a rationale for less extensive resection, in Europe, up to 75% of lobectomized patients may ultimately be candidates for such therapy (50– 52).”
Giovanella, L., Suriano, S., Castellani, M., Ceriani, L., & Verburg, F. A. (2011) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31821a29eb · Cited by 5
Self-citation
Cited by
Alexander, E. K., & Cibas, E. S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00101-2 · Cited by 254
Seeking optimization of LT4 treatment in patients with differentiated thyroid cancer
Stramazzo, I., Capriello, S., Antonelli, A., Fallahi, P., Centanni, M., & Virili, C. (2022) · HORMONES · doi:10.1007/s42000-022-00376-9 · Cited by 9
“The choice is based on the major Society guidelines on differentiated thyroid cancer (DTC representing 90% of thyroid tumors) [2, 3], depending on tumor size, invasion, local or distant metastasis, and response to therapy (see below).”
Background
Metadata
- Authors
- Luster, M., Aktolun, C., Amendoeira, I., Barczyński, M., Bible, K. C., Duntas, L. H., Elisei, R., Handkiewicz-Junak, D., Hoffmann, M., Jarząb, B., Leenhardt, L., Musholt, T. J., Newbold, K., Nixon, I. J., Smit, J., Sobrinho-Simões, M., Sosa, J. A., Tuttle, R. M., Verburg, F. A., Wartofsky, L., & Führer, D.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 2019-01
- Volume
- 29
- Issue
- 1
- Pages
- 7-26
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W2903130587
- Cited by
- 181
- References
- 120
- FWCI
- 12.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.